ストックスクリーナーアプリを入手
65.26
1.63%
-1.17
前日終値:
$66.43
開ける：
$66
24時間の取引高:
475.49K
Relative Volume:
0.57
時価総額：
$4.06B
収益：
$45.48M
当期純損益:
$169.95M
株価収益率:
24.91
EPS:
2.62
ネットキャッシュフロー:
$230.85M
1週間 パフォーマンス:
-0.91%
1か月 パフォーマンス:
+10.67%
6か月 パフォーマンス:
+39.40%
1年 パフォーマンス:
+47.28%
1日の値動き範囲:
$64.81
$66.53
1週間の範囲:
$63.82
$68.26
52週間の値動き範囲:
$33.31
$68.26
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
名前
Protagonist Therapeutics Inc
セクター
電話
(510) 474-0170
住所
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
PTGX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PTGX
Protagonist Therapeutics Inc
|
65.27 | 4.13B | 45.48M | 169.95M | 230.85M | 2.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
405.80 | 100.41B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
607.00 | 59.59B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
463.70 | 59.77B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
774.71 | 45.14B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
345.21 | 37.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-17 | 開始されました | Barclays | Overweight |
| 2025-09-12 | 開始されました | Leerink Partners | Outperform |
| 2025-06-17 | 開始されました | Citigroup | Buy |
| 2024-12-06 | 開始されました | BMO Capital Markets | Outperform |
| 2024-12-06 | 開始されました | Goldman | Neutral |
| 2024-11-05 | 開始されました | Wedbush | Outperform |
| 2024-09-24 | 開始されました | TD Cowen | Buy |
| 2024-09-09 | 開始されました | Truist | Buy |
| 2023-10-30 | 開始されました | CapitalOne | Overweight |
| 2023-05-25 | 再開されました | Jefferies | Buy |
| 2022-08-25 | 開始されました | JMP Securities | Mkt Outperform |
| 2022-02-11 | 開始されました | BTIG Research | Buy |
| 2021-10-12 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-10-11 | アップグレード | Northland Capital | Market Perform → Outperform |
| 2021-09-20 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-05-24 | 開始されました | JMP Securities | Mkt Outperform |
| 2021-05-24 | 開始されました | Northland Capital | Outperform |
| 2021-01-06 | 開始されました | JP Morgan | Overweight |
| 2020-12-16 | 開始されました | Piper Sandler | Overweight |
| 2020-09-18 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-07-15 | 開始されました | Jefferies | Buy |
| 2020-05-18 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-07-08 | 開始されました | H.C. Wainwright | Buy |
| 2019-05-09 | アップグレード | Stifel | Hold → Buy |
| 2018-12-06 | 開始されました | Nomura | Buy |
| 2018-01-29 | 開始されました | Stifel | Buy |
| 2017-07-21 | 開始されました | BTIG Research | Buy |
すべてを表示
Protagonist Therapeutics Inc (PTGX) 最新ニュース
Short interest data insights for Protagonist Therapeutics Inc.M&A Rumor & High Accuracy Swing Trade Signals - newser.com
Why Protagonist Therapeutics Inc. stock could be next big winner2025 Analyst Calls & Growth Oriented Trading Recommendations - newser.com
Can Protagonist Therapeutics Inc. stock hit record highs againJuly 2025 WrapUp & Daily Profit Focused Stock Screening - newser.com
Historical volatility pattern of Protagonist Therapeutics Inc. visualizedLong Setup & Real-Time Buy Signal Notifications - newser.com
Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025 - Sarasota Herald-Tribune
Protagonist Therapeutics (NASDAQ:PTGX) Shares Down 5.1%What's Next? - MarketBeat
Protagonist Therapeutics Hits New 52-Week High of $68.26, Up 103% - Markets Mojo
Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025 - Corpus Christi Caller-Times
What analysts say about Protagonist Therapeutics Inc stockGlobal Market Influence & Free Discover Massive Upside Stocks - earlytimes.in
What drives Protagonist Therapeutics Inc stock priceMarket Liquidity Analysis & Market Monitoring and Alerts - earlytimes.in
Protagonist Therapeutics (MEX:PTGX) Tariff Resilience Score : 5/10 (As of Sep. 27, 2025) - GuruFocus
Protagonist Therapeutics stock reaches all-time high at 66.7 USD - Investing.com India
Protagonist Therapeutics stock reaches all-time high at 66.7 USD By Investing.com - Investing.com Canada
Protagonist Therapeutics Hits New 52-Week High of $66.70, Up 98.82% - Markets Mojo
7,530 Shares in Protagonist Therapeutics, Inc. $PTGX Acquired by Palumbo Wealth Management LLC - MarketBeat
Protagonist Therapeutics Hits New 52-Week High of $65.08 - Markets Mojo
Assenagon Asset Management S.A. Increases Stock Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Insider Sell: William Waddill Sells 4,000 Shares of Protagonist Therapeutics Inc (PTGX) - GuruFocus
Protagonist Therapeutics (NASDAQ:PTGX) Director Sells $257,000.00 in Stock - MarketBeat
Waddill, Protagonist Therapeutics director, sells $257k in shares By Investing.com - Investing.com Canada
Protagonist Therapeutics (NASDAQ:PTGX) Reaches New 12-Month HighShould You Buy? - MarketBeat
Protagonist Therapeutics Hits New 52-Week High of $64.59, Up 94.48% - Markets Mojo
Protagonist Therapeutics, Inc. $PTGX Shares Acquired by Exchange Traded Concepts LLC - MarketBeat
Protagonist Announces Presentations of Clinical Data with Icotrokinra in Plaque Psoriasis and Preclinical Data with PN-881 at the EADV 2025 Congress - Cincinnati Enquirer
Voya Investment Management LLC Has $2.89 Million Stake in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Strs Ohio Takes $919,000 Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Announces Icotrokinra Application for Approval in Plaque Psoriasis Submitted to the European Medicines Agency - Lubbock Avalanche-Journal
Protagonist Therapeutics (NASDAQ:PTGX) Sets New 12-Month HighHere's Why - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) Coverage Initiated at Barclays - MarketBeat
Protagonist Therapeutics Hits New 52-Week High of $63.30 - Markets Mojo
Analysts Set Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Target Price at $68.08 - MarketBeat
Protagonist Therapeutics' (PTGX) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) Coverage Initiated by Analysts at Barclays - MarketBeat
Protagonist Therapeutics Hits New 52-Week High at $62.21 - Markets Mojo
Aug Big Picture: Will Protagonist Therapeutics Inc benefit from AI trendsMarket Volume Summary & Precise Entry and Exit Recommendations - khodrobank.com
Bank Watch: Can Protagonist Therapeutics Inc be the next market leaderMarket Trend Report & AI Enhanced Trade Execution Alerts - خودرو بانک
What is Leerink Partnrs' Estimate for PTGX Q3 Earnings? - MarketBeat
Protagonist Therapeutics, Inc. $PTGX Shares Bought by Inspire Investing LLC - MarketBeat
Protagonist Therapeutics stock hits all-time high of 61.89 USD By Investing.com - Investing.com Canada
Protagonist Therapeutics Inc (PTGX) 財務データ
収益
当期純利益
現金流量
EPS
1.97%
大文字化:
|
ボリューム (24 時間):